FlexCAT · Training program to engage flexible and disordered protein targets for therapeutic development: The oncogene β-catenin as showcase.

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Цел на проекта

Traditionally, proteins have been categorized into two main structural classes: ordered and disordered. Large parts of the human proteome contain intrinsically disordered regions (IDRs), which are highly flexible and only sometimes adopt a distinct conformation upon interaction with a binding partner. IDRs are fundamental to intracellular signalling and protein interaction networks, particularly transcriptional regulation. Dysregulation of these processes is strongly associated with diseases including cancer and neurodegenerative disorders. However, targeting IDRs is challenging because of their dynamic nature and the lack of well-defined binding pockets. IDR targets have therefore been largely underrepresented in the pharmaceutical industry and the competencies for characterizing and targeting IDRs are lacking.The aim of the FlexCAT doctoral training network (DN) is to equip a cohort of doctoral candidates (DCs) with unique expertise and knowledge in characterizing and targeting IDRs. We aim to challenge and complement the limitations of classical small molecule approaches that were primarily developed to target druggable pockets within folded proteins. The DCs will carry out challenging research projects with the aim to assemble, expand, develop and apply novel approaches to understand and exploit disordered targets and IDRs. We will focus on utilizing β-catenin, a central therapeutic target and prime example of an IDR-related drug targeting challenge. Alongside the individual research projects, the DCs will expand their knowledge and transferrable skills through a structured training program, including secondments and contributions from the non-academic sector. The outcome of the FlexCAT DN will be increased understanding of the role of disordered targets and IDRs, their implications in disease and particularly cancer, while also developing practical strategies for exploring the therapeutic intervention of alternative IDR-related protein targets.

Оригинален текст от CORDIS (на английски).

Участници

• TECHNISCHE UNIVERSITAET WIEN · WienКоординаторАвстрия
• BOEHRINGER INGELHEIM RCV GMBH & CO KG · WienАвстрия
• DIREKTORATET FOR MEDISINSKE PRODUKTER · OSLOНорвегия
• EnzyTag BV · NuthНиво градНидерландия
• Figlinq B.V. · AmsterdamНиво градНидерландия
• GENENTECH INC · SOUTH SAN FRANCISCO CAСъединени щати
• GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS · GottingenГермания
• HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH · NeuherbergГермания
• ISTITUTO EUROPEO DI ONCOLOGIA SRL · MilanoИталия
• JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG · WuerzburgГермания
• MEDIZINISCHE UNIVERSITAT GRAZ · GrazАвстрия
• PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV · UtrechtНидерландия
• STICHTING AMSTERDAM UMC · AmsterdamНидерландия
• STICHTING ONCODE INSTITUTE · UtrechtНидерландия
• TECHNISCHE UNIVERSITAET MUENCHEN · MuenchenГермания
• THE HEBREW UNIVERSITY OF JERUSALEM · JerusalemИзраел
• THE UNIVERSITY OF SUSSEX · BrightonОбединеното кралство
• UNIVERSITA DEGLI STUDI DI MILANO · MilanoИталия
• UNIVERSITE DU LUXEMBOURG · ESCH-SUR-ALZETTEЛюксембург
• UNIVERSITEIT UTRECHT · UtrechtНидерландия
• UNIVERSITEIT VAN AMSTERDAM · AmsterdamНидерландия

Връзки

• Виж в CORDIS
• DOI: 10.3030/101311592